Astria Therapeutics filings document the company's former Nasdaq-listed common stock, clinical-stage biopharmaceutical operations, material agreements, shareholder voting matters, and completed corporate-status changes. Its 8-K reports covered operating and financial results, the navenibart license agreement for Japan, merger-related agreements, security-holder voting results, and loan-guarantor obligations after the transaction closing.
The filing record also includes Form 25 removal of Astria common stock from Nasdaq listing and Form 15 termination or suspension of Exchange Act reporting duties. Those filings record Astria's transition into a wholly owned subsidiary of BioCryst Pharmaceuticals and the end of separate public-company registration for its common stock.
Vestal Point Capital and Ryan Wilder report owning 0 shares, or 0%, of Astria Therapeutics common stock as of December 31, 2025. They previously filed as significant holders but now certify beneficial ownership of 5 percent or less of the class.
The filing is made on Schedule 13G/A, with the reporting persons describing themselves as an investment adviser and an individual control person, and stating that any securities were acquired and held in the ordinary course of business, not to change or influence control of Astria Therapeutics.
Glazer Capital, LLC and Paul J. Glazer report beneficial ownership of 3,776,154 shares of Astria Therapeutics, Inc. common stock, equal to 6.61% of the outstanding class as of 12/31/2025.
All voting and dispositive power over these shares is shared, with no sole voting or dispositive authority reported. The filers certify that the securities were acquired and are held as a passive investment, not for the purpose of changing or influencing control of Astria Therapeutics.
Astria Therapeutics, Inc. filed an amended Schedule 13D showing that investment entities affiliated with Perceptive Advisors no longer own any of its common stock. The filing reports that Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd., and Perceptive Xontogeny Venture Fund, L.P. each hold 0 shares and 0% of the class.
This change follows the previously announced acquisition of Astria by BioCryst under a merger agreement. The merger was completed on January 23, 2026, and Astria ceased to exist as a separate entity, which eliminated the reporting persons’ beneficial ownership in the company’s shares.
Astria Therapeutics, Inc. completed a cash merger in which each share of its Class A common stock was converted into the right to receive $8.55 in cash, without interest, as of the closing on January 23, 2026.
Funds and accounts managed by Magnetar-affiliated entities previously held 3,431,007 shares, which were cancelled and converted into this cash consideration. The filing states that, following the merger, Magnetar Financial LLC, Magnetar Capital Partners, Supernova Management LLC, and David J. Snyderman each report beneficial ownership of 0 shares, or 0% of the class.
The amendment also notes that since their October 24, 2025 report, the reporting persons purchased an additional 118,805 shares for an aggregate of $1,501,294.83 on behalf of the funds before all holdings were cashed out in the merger.